University of California Los Angeles (UCLA)

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma (2024) Saner FA, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, et al. Journal article Domain generalization across tumor types, laboratories, and species — Insights from the 2022 edition of the Mitosis Domain Generalization Challenge (2024) Aubreville M, Stathonikos N, Donovan TA, Klopfleisch R, Ammeling J, Ganz J, Wilm F, et al. Journal article Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024) Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Journal article The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects (2024) Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, et al. Journal article Hypoxia Attenuates Pressure Overload-Induced Heart Failure (2024) Froese N, Szaroszyk M, Galuppo P, Visker JR, Werlein C, Korf-Klingebiel M, Berliner D, et al. Journal article Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank (2024) Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Ventura IB, Dourado E, Bozan F, et al. Journal article Spliceosome malfunction causes neurodevelopmental disorders with overlapping features (2024) Li D, Wang Q, Bayat A, Battig MR, Zhou Y, Bosch DG, van Haaften G, et al. Journal article Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project (2024) Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, et al. Journal article Quantum enhanced electric field mapping within semiconductor devices (2024) Scheller D, Hrunski F, Schwarberg J, Knolle W, Soykal ÖO, Udvarhelyi P, Narang P, et al. Journal article, Letter A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024) Hughes BG, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, et al. Journal article